Detalles de la búsqueda
1.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood
; 119(26): 6226-33, 2012 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22592608
2.
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Blood
; 120(26): 5185-7, 2012 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23024237
3.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol
; 29(18): 2493-8, 2011 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21576633
Resultados
1 -
3
de 3
1
Próxima >
>>